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Background: Left ventricular diastolic dysfunction (LVDD) is considered a precursor of diabetic cardiomyopathy,
while insulin resistance (IR) is a precursor of type 2 diabetes mellitus (T2DM) and independently predicts heart
failure (HF). We assessed whether IR and abnormalities of the glucose metabolism are related to LVDD.
Methods: We included 208 patients with normal ejection fraction, 57 (27%) of whom had T2DM before inclusion.
In subjects without T2DM, an oral glucose tolerance test (oGTT) was performed. IR was assessed using the
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). The lower limit of the top quartile of the HOMA-IR
distribution (3.217) was chosen as threshold for IR. LVDD was verified according to current guidelines.
Results: IR was diagnosed in 38 (18%) patients without a history of diabetes. The prevalence of LVDD was 92% in
subjects with IR vs. 72% in patients without IR (n = 113), respectively (p = 0.013). In the IR group, the early diastolic
mitral inflow velocity (E) in relation to the early diastolic tissue Doppler velocity (averaged from the septal and
lateral mitral annulus, E’av) ratio (E/E’av) was significantly higher compared to those without IR (9.8 [8.3-11.5] vs. 8.1
[6.6-11.0], p = 0.011). This finding remains significant when patients with IR and concomitant T2DM based on oGTT
results were excluded (E/E’av ratio 9.8 [8.2-11.1)] in IR vs. 7.9 [6.5-10.5] in those without both IR and T2DM, p =
0.014). There were significant differences among patients with and without LVDD regarding the HOMA-IR (1.71
[1.04-3.88] vs. 1.09 [0.43-2.2], p = 0.003). The HOMA-IR was independently associated with LVDD on multivariate
logistic regression analysis, a 1-unit increase in HOMA-IR value was associated with an odds ratio for prevalent
LVDD of 2.1 (95% CI 1.3-3.1, p = 0.001). Furthermore, the E/E’av ratio increases along the glucose metabolism status
from normal glucose metabolism (7.6 [6.2-10.1]) to impaired glucose tolerance (8.8 [7.4-11.0]) and T2DM (10.5 [8.1-
13.2]), respectively (p < 0.001).
Conclusions: Insulin resistance is independently associated with LVDD in subjects without overt T2DM. Patients
with IR and glucose metabolism disorders might represent a target population to prevent the development of HF.
Screening programs for glucose metabolism disturbances should address the assessment of diastolic function and
probably IR.
Background
Heart failure (HF) is increasingly common worldwide with
an estimated prevalence of 2-3% [1]. It has been recog-
nized that a large percentage of patients presenting with
HF have a normal left ventricular ejection fraction
(diastolic heart failure or “heart failure with normal ejec-
tion fraction”, HFnEF), a condition remaining frequently
undiagnosed in clinical practice. Recent data suggest that
morbidity and mortality from HFnEF is nearly equal to
that of systolic HF [2,3]. In the general population, which
was mostly free of clinical signs of HF, left ventricular dia-
stolic dysfunction (LVDD), the precursor of diastolic HF,
was a powerful and independent predictor of death [4].
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(T2DM) has reached epidemic proportions, with an esti-
mated further increase in worldwide prevalence [5]. Stu-
dies have identified diabetes as a powerful and
independent risk factor for the development and prog-
nosis of HF [6], referred to as diabetic cardiomyopathy
[7]. Several studies have demonstrated left ventricular
diastolic dysfunction (LVDD) to represent the first man-
ifestation of myocardial involvement in diabetes [8-10],
which is to be a key component of diabetic cardiomyo-
pathy. Furthermore, LVDD can precede the develop-
ment of diabetes [11], suggesting that LVDD is not
exclusively a complication of diabetes but rather a coex-
isting condition.
The development of diabetic cardiomyopathy is likely
multifactorial, with putative mechanisms including
metabolic disturbance, changes in the extracellular
matrix (ECM) components, small vessel disease, auto-
nomic dysfunction and insulin resistance (IR). Insulin
resistance may precede diabetes by a decade or more
and is a pathogenic factor for T2DM [12]. Furthermore,
IR has been shown to be an independent predictor of
cardiovascular disease in T2DM [13] and predicted sys-
tolic HF incidence independently of established risk fac-
tors including diabetes in the community [14].
Little is known about the interactions of IR and
LVDD, both frequently overlooked but nevertheless ser-
ious comorbidities of subjects with known or suspected
heart disease. The aim of the present study was to
explore the possible link between LVDD, IR and glucose
metabolism disturbances in patients with suspected or
known heart disease using definitions considering the




Two hundred-eight consecutive hospitalized subjects
referred to elective coronary angiography for stable or
suspected coronary artery disease (CAD) were enrolled in
this ongoing study. Patients with the need for coronary
revascularisation either with angioplasty or coronary
bypass surgery were excluded from further analysis. The
protocol was approved by the local Ethics Committee,
a n ds i g n e di n f o r m e dc o n s e n tw a so b t a i n e df r o ma l l
patients. Inclusion criteria were scheduled coronary
angiography and age 18-80 years. Exclusion criteria were
known CAD with progressive chest pain within the last
month, coronary angioplasty < 6 weeks, hypertrophic car-
diomyopathy, moderate-to-severe valvular heart disease,
uncontrolled hypertension, atrial fibrillation or other
severe arrhythmias, or serum-creatinine > 2.5 mg/dl. In
patients without diabetes, a standardized oral glucose tol-
erance test (oGTT) was performed (75 g glucose)
according to the World Health Organization protocol as
previously described [15]. Body mass index (BMI) was
calculated as weight (kg)/height (m
2). Abdominal girth
was measured around the abdomen at the level of the
belly button, and hip girth was measured at the level of
maximal protrusion of the gluteal muscles.
Echocardiography
Echocardiography for the diagnosis of LVDD was per-
formed using a standard ultrasound system (Vingmed
Vivid 7, General Electric, Milwaukee, Wisconsin). Left
ventricular ejection fraction (EF) was measured based
on the modified biplane Simpson method. The left
atrium volume index [16] was calculated using the
biplane area-length method [17]. Dimensions were
recorded by standard techniques according to current
guidelines [17]. Left ventricular mass index (LVMi) was
calculated by the Devereux formula indexed to the body
surface area [17]. Conventional transmitral flow was
measured with pw-doppler. Early (E), late atrial (A)
transmitral peak flow velocities and the ratio (E/A) were
measured and three consecutive beats were averaged.
Pulsed wave tissue Doppler imaging (TDI) was per-
formed at the junction of the septal and lateral mitral
annulus and three consecutive beats were averaged.
Early diastolic velocities (E’medial, E’ lateral) were
recorded; the mean value (E’ average) from E’ at the
medial and lateral mitral annulus was determined.
Ratios of E/E’medial, E/E’lateral and E/E’(average) were
calculated. Diastolic dysfunction was classified according
to the common consensus paper of the American and
European Society of Echocardiography (ASE, ESC) [18],
including comprehensive evaluation of diastolic function
with conventional Doppler tissue Doppler techniques.
All examinations were performed by two physicians
experienced in the technique, and analyses of LVDD
were blinded for IR and glucose metabolism status.
Laboratory analysis
Insulin resistance was assessed by using Homeostasis
Model Assessment of Insulin Resistance (HOMA-IR)
and Quantitative Insulin Sensitivity Check Index
(QUICKI) in subjects without a history of diabetes
before inclusion into the study. The HOMA-IR was cal-
culated from the formula: HOMA-IR= fasting glucose
(mg/dl) × Insulin (μU/ml)/405 [19]. QUICKI was
assessed with the formula: QUICKI = 1/[log glucose
(mg/dL)+log insulin (μU/mL)] [20]. The lower limit of
the top quartile of HOMA-IR distribution (i.e. 3.217)
was chosen as the threshold for IR.
Statistical analysis
All analyses were performed using SPSS statistical soft-
ware (SPSS 17.0, Chicago, IL). The data are presented as
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absolute number (%) for categorical variables unless
otherwise specified. A P value < 0.05 was considered
statistically significant and adjusted for multiple compar-
isons using Bonferroni adjustment. Non-parametric
tests for group differences between categories of IR and
glucose metabolism disorders were performed. The Wil-
coxon-Mann-Whitney-Test was used for the comparison
of two independent groups, and the Kruskal Wallis Test
was used for more than two independent samples. The
Jonckheere-Terpstra test was used to detect effects
across ordered categories. Fisher’s Test was used for the
comparison of two sets of binary variables, and the c
2
test for the comparison of more than 2 sets of categori-
cal variables. To investigate a possible relation between
variables, the Pearson’s linear correlation coefficients
were calculated. Multivariate analysis of covariance and
logistic regression models including variable most pre-
dictive for the dependent variables were built.
Results
Patients characteristics
We included 208 patients in the study (48% woman, 64
± 11 years), 57 (27%) of whom had T2DM before inclu-
sion (mean duration of diabetes 9.6 ± 9.7 years). An
oGTT was performed in 151 individuals, of whom 64
(31%) had a normal glucose tolerance (NGT), 54 (26%)
had impaired glucose tolerance (IGT) and 33 (16%) had
a new detected diabetes (ND-T2DM). Overall, 90 (43%)
individuals had T2DM at inclusion. A metabolic syn-
d r o m e( M e t S )w a sd i a g n o s e di n1 1 7( 5 9 % )p a t i e n t s
according to the amended National Cholesterol Educa-
tion Program’s Adult Treatment Panel III (ATP-III)
guidelines[21]. In the MetS group, 46 (39%) had T2DM
before inclusion, 33 (28%) had ND-T2DM, 22 (18%) had
IGT and 16 (14%) had NGT, whereas in the group with-
out MetS, 57% had NGT, 37% IGT and 6% T2D, respec-
tively (p < 0.001). In the IR group, 25 (66%) patients
were classified as having MetS, whereas 34 (32%) with-
out IR had a MetS (p < 0.001). In subjects with IR, the
prevalence of obesity, defined as BMI > 30kg/m
2,w a s
48% compared to 27% in subjects without IR (p =
0.021). Demographics and clinical variables for patients
with or without IR, NGT, IGT, and T2DM are shown in
table 1 and medications are shown in table 2.
Overall prevalence of diastolic dysfunction
The parameters of cardiac assessment are presented in
table 3. One hundred seventy (82%) patients had evidence
of LVDD of any degree according to the recent guidelines
criteria publishes by Nagueh et al. [18]. A more severe
form of LVDD (LVDD grade II or grade III, pseudonormal
pattern) was observed in 58 (28%) patients, whereas 112
(54%) subjects had mild LVDD (grade I) and 38 (18%)
patients had normal diastolic function. In subjects with
LVDD of any grade, the BMI (27 [25-32] kg/m
2) and the
waist-circumference (103 [96-115] cm) was significantly
higher compared to those without LVDD (BMI 25 [23-30]
kg/m
2 and waist circumference 98 [88-108] cm, p = 0.022
and p = 0.009, respectively).
Diastolic function and glucose metabolism
The prevalence of LVDD increased with impaired glu-
cose metabolism (table 3). The highest prevalence was
found in those with T2DM as compared to those with
NGT (93% vs. 62%, p < 0.001) and those with IGT (93%
vs. 85%, p = 0.147). The prevalence was similar in sub-
jects with long standing T2DM and new detected
T2DM based on oGTT results (95% vs. 91%, p = 0.665).
The status of glucose metabolism remains a significant
predictor of LVDD in a logistic regression model
adjusted for CAD, hypertension, age, sex, history of pre-
vious myocardial infarction, history of previous coronary
angioplasty, EF and the oGTT results (p < 0.001).
The prevalence of moderate to severe LVDD (grade II
or III) increased with the degree of the glucose metabo-
lism disturbance (p < 0.001, figure 1). In addition, the E/
E’(average) ratio, which is indicative for of diastolic dys-
function and elevated left ventricular filling pressures,
increases from NGT (7.6 [6.2-10.1]) to IGT (8.8 [7.4-
11.0]) and T2DM (10.5 [8.1-13.2]), respectively (p <
0.001, figure 2). Importantly, the E/E’(average) ratio
remained significantly higher in the IGT group com-
pared to the NGT group when excluding patients with
overt diabetes (p = 0.017). Furthermore, across the
whole cohort, the E/E’(average) ratio correlated signifi-
cant with the HbA1c (r = 0.150, p = 0.037) and with the
two hour postprandial glucose level (r = 0.22, p =
0.008). The E/E’(average) ratio in patients above the
lower limit of the top quartile of HbA1c distribution
(>6.55%) was 10.2 [8.2-13.2] vs. 7.7 [6.2-10.5] in subjects
below the upper limit of the lowest quartile (HbA1c <
5.60%, p = 0.001). Similar, the E/E’septal ratio was sig-
nificantly higher in patients in the upper quartile group
compared to subjects in the lowest quartile group (12.1
[10.0-14.5] vs. 9.1 [7.1-12.0], p = 0.001).
Among other echocardiographic parameter used as
criteria for the presence of LVDD, the glucose metabo-
lism was associated with the LAi, E’septal, E’lateral and
E’average. The LAi increases from NGT to IGT and
T2DM (p = 0.001), whereas E’septal, E’lateral and
E’average decreases (p = 0.001, p = 0.002, p < 0.001,
table 3), respectiverly.
Diastolic function and HOMA-IR
38 subjects had IR, defined as an HOMR-IR above the
lower limit of the top quartile of HOMA-IR distribution
(>3.217), 92% of whom had evidence of LVDD, whereas
Dinh et al. Cardiovascular Diabetology 2010, 9:63
http://www.cardiab.com/content/9/1/63
Page 3 of 1272% of subjects with a HOMA-IR below this threshold
(n = 113) had evidence of LVDD (p < 0.001). The preva-
lence of LVDD increases along the quartile range of the
HOMA-IR (figure 3, p = 0.048). The prevalence of mild
or moderate to severe LVDD (grade II or grade III) was
61% and 32% in the IR group vs. 48% and 24% in the
non IR group, respectively (c
2 in a 2 × 3 table, p =
0.036).
In subjects with LVDD of any grade, the HOMA-IR was
1.71, [1.04-3.88] vs. 1.09 [0.43-2.2] in subjects with normal
diastolic function (p = 0.003), and the QUICKI in the
LVDD group was 0.35 [0.31-0.38] vs. 0.37 [0.34-0.44] in
individuals without IR (p = 0.005), respectively. The
HOMA-IR was independent associated with LVDD on
multivariate logistic regression analysis adjusted for CAD,
hypertension, age, sex, history of previous myocardial
infarction, history of previous coronary angioplasty, EF
and history of T2DM before inclusion, a 1-unit increase in
HOMA-IR value was associated with an odds ratio for
prevalent LVDD of 2.1 (95% CI 1.3-3.1, p = 0.001).
The E/E’(average) ratio (p = 0.011) and the E/E’septal
ratio (p = 0.014) were significantly higher in subjects with
IR compared to subjects without IR, both functional para-
meter indicative for left ventricular diastolic dysfunction
with concomitant elevated left ventricular filling pressures
(Figure 4). Excluding subjects with a history of diabetes
before inclusion, a significant correlation remains between
the HbA1c and the E/E’(average) (r = 0.204, p = 0.015)
Table 1 Demographics, clinical variables and laboratory parameters in subjects with or without IR and in different
degrees of glucose disturbance disorders
Variable IR (+) IR(-) p-value
a NGT IGT T2DM
# p-value
a
n (%) 38 (18) 113 (54) - 64 (31) 54 (26) 90 (43) -
Variables
Age (years) 62 (53-72) 65 (56-72) 0.604 62 (54-69) 61 (51-70) 71 (63-75) < 0.001*
Female sex, n (%) 17 (45) 53 (47) 0.484 30 (46) 23 (42) 46 (51) 0.606
WC (cm) 103 (97-118) 100 (92-111) 0.031* 99 (90-110) 100 (95-111) 109 (98-117) < 0.001*
HC (cm) 105 (98-114) 99 (92-109) 0.019* 100 (91-109) 99 (95-110) 109 (100-116) < 0.001*
BMI (kg/m
2) 28 (26-35) 26 (24-30) 0.001* 25 (24-30) 26 (24-31) 29 (26-32) < 0.001*
SBP, mmHg 135 (128-142) 130 (120-137) 0.020* 128 (120-135) 130 (126-140) 136 (130-142) < 0.001*
DBP, mmHg 80 (75-82) 80 (70-82) 0.863 80 (70-80) 80 (74-84) 80 (73-84) 0.055
MAP (mmHg) 96 (91-101) 96 (90-100) 0.258 94 (87-98) 96 (91-101) 98 (93-102) 0.003*
Puls-Pressure 57 (48-60) 50 (42-58) 0.031* 50 (41-58) 52 (44-60) 54 (50-61) 0.005*
CV risk factors
HTN, n (%) 33 (89) 95 (84) 0.319 49 (76) 47 (89) 84 (95) 0.002*
HLP, n (%) 23 (61) 73 (64) 0.396 37 (58) 36 (67) 62 (70) 0.305
Smoker, n (%) 2 (5) 21 (19) 0.037* 12 (19) 10 (19) 10 (12) 0.366
Family Hx CAD 24 (63) 59 (52) 0.162 29 (45) 35 (64) 42 (27) 0.065
Hx Stroke, n (%) 0 (0) 4 (3) 0.309 3 (5) 1 (2) 4 (4) 0.674
Labaratory data
Fasting glucose 100 (105-118) 92 (86-98) < 0.001* 89 (84-94) 104 (90-112) 105 (98-118) < 0.001*
2h-PG (mg/dl) 183 (138-233) 132 (112-161) < 0.001* 117 (99-130) 156 (139-164) 225 (212-248)
b < 0.001*
Insulin (μU/L) 18.5 (15.7-24.0) 5.0 (3.0-7.0) < 0.001* 5.0 (2.0-7.0) 8.0 (5.0-15.0) 9.5 (6.0-18.0)
b < 0.001*
HOMA-IR 5.09 (3.96-6.61) 1.2 (0.69-1.77) < 0.001* 1.10 (0.44-1.56) 1.86 (1.10-3.85) 2.53 (1.62-4.78)
b <0.001*
QUICKI 0.30 (0.29-0.31) 0.37 (0.35-0.40) <0.001* 0.38 (0.35-0.44) 0.35 (0.31-0.38) 0.33 (0.30-0.35)
b 0.001*
HbA1c (%) 5.9 (5.7-6.3) 5.7 (5.5-6.1) 0.033* 5.7 (5.4-6.0) 5.8 (5.6-6.1) 6.6 (6.0-7.4) <0.001*
LDL-Ch (mg/dl) 114 (99-136) 109 (90-130) 0.207 109 (92-136) 115 (99-130) 103 (77-130) 0.095
HDL- Ch (mg/dl) 49 (38-57) 54 (4566) 0.044* 54 (46-68) 53 (47-63) 46 (38-59) 0.001*
Total- Ch (mg/dl) 204 (177-222) 191 (171-222) 0.529 189 (175-228) 200 (173-220) 188 (63-221) 0.300
Triglyceride 142 (100-202) 124 (90-169) 0.234 120 (89-157) 126 (95-165) 162 (118-258) 0.001*
Lipoprotein (a) 13 (5-27) 14 (5-39) 0.729 11 (5-35) 15 (4-38) 5 (13-35) 0.944
Creatinine (mg/dl) 0.90 (0.80-1.20) 0.89 (0.77-0.98) 0.253 0.88 (0.75-0.96) 0.90 (0.76-1.0) 0.79 (0.90-1.05) 0.643
hsCRP (mg/dl) 0.2 (0.1-0.5) 0.2 (0.1-0.6) 0.961 0.2 (0.10-0.8) 0.2 (0.1-0.45) 0.3 (0.2-0.6) 0.113
Values are median (interquartile range) or n (%).
a Mann-Whitney-Test, Jonckheere-Terpstra test, Fisher or c
2 Test were used as appropriate,
b = 33 subjects with
new detected diabetes * statistically significant (p < 0,05).
# Subjects with diabetes before inclusion or new detected diabetes. BMI = Body mass index, CAD =
Coronary Artery Disease, Ch = Cholesterol, CV = Cardiovascuklar, DBP = Diastolic blood pressure, HC = Hip circumference, HLP = Hyperlipidaemia, hsCRP = High
sensitive CRP, HTN = Hypertension, Hx = history of, IR = insulin resistance, MAP = mean arterial pressure, PG = Postprandial glucose, SBP = Systolic blood
pressure, WC = Waist circumference
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the two hour postprandial glucose level was significantly
correlated with the E/E’(average) (r = 0.219, p = 0.008)
and the E/E’septal ratio (r = 0.214, p = 0.009). Further-
more, there was a significant correlation between the
HbA1c und the LAi (r = 0.185, p = 0.028).
Discussion
The main finding of the present study is that IR is asso-
ciated with LVDD independent of overt diabetes. These
finding persist after adjustment for CAD, hypertension,
age, sex, history of previous myocardial infarction, his-
tory of previous coronary angioplasty, EF and glycaemic
control. To our knowledge, this is the first study that
demonstrated an association in a population of patients
without a history of diabetes focusing on the published
current guidelines for the diagnosis of LVDD.
Furthermore, our date confirm the observations that
T2DM is associated with LVDD [9], which is considered
a precursor of diabetic cardiomyopathy. In addition, we
were able to extend the findings in previous studies
showing the association between LVDD and IGT.
These findings are in line with a limited number of
studies that assessed the relationship between predia-
betes and LVDD mainly in population based studies
[11]. Nevertheless, there are some concerns about meth-
odological issues involving the identification of LVDD
patients in the previous studies. The criteria used to
define LVDD were highly variable and predominantly
did not consider the diagnostic guidelines [22].
Furthermore, most of these studies did not screen for
the presence of CAD using coronary angiography. Since
CAD has been shown to be associated with LVDD, the
lack of information on coronary morphology is a poten-
tial source of bias towards an increased prevalence and
severity of CAD in patients with LVDD. In contrast, the
present study focuses on patient recruitment according
to the published current guidelines for the diagnostic
workup of LVDD in subjects well characterized for the
degree of abnormality in plasma glucose levels and cor-
onary morphology.
We found that IR, as estimated by the HOMA-IR [19],
was strongly associated with LVDD in patient without a
history of overt diabetes. In a logistic regression model
with LVDD as the dependent variable, this association
was found independently of established classic risk fac-
tors for LVDD such as female sex, age, CAD, hyperten-
sion and diabetic state. In addition, high sensitive c-
reactive protein (hsCRP) level sd i dn o ta c ts i g n i f i c a n t l y
to the model. Given the fact that previous studies sug-
gested suggest a link between low-grade inflammation
and the presence of LVDD [23,24], it is not likely that
low grade inflammation was a significant source of bias
in our cohort.
As expected, the presence and degree of a glucose
metabolism disorder was another strong predictor for
Table 2 Medications
Variable IR (+) IR(-) p-value
a NGT IGT T2DM
5# p-value
a
n (%) 38 (18) 113 (54) - 64 (31) 54 (26) 90 (43) -
Glucose lowering treatment
Metformin, n (%) 0 (0) 1 (0.9) 0.748 0 (0) 1 (2) 64 (71) <0.001*
Sulfonylurea, n (%) 0 (0) 1 (0.9) 0.748 0 (0) 0 (0) 1 (1) <0.001*
Insulin therapy, n (%) 0 (0) 0 (0) - 0 (0) 0 (0) 24 (34) <0.001*
Thiazolidinediones, n (%) 0 (0) 0 (0) - 0 (0) 0 (0) 2 (2) 0.266
Glinide, n (%) 0 (0) 0 (0) - 0 (0) 0 (0) 2 (2) 0.266
Hypertension treatment
Beta-blocker, n (%) 23 (61) 72 (63) 0.434 33 (52) 39 (72) 62 (69) 0.033*
AT1 receptor blocker, n (%) 5 (13) 16 (14) 1.000 9 (14) 6 (11) 15 (17) 0.653
ACE-inhibitor, n (%) 24 (36) 65 (58) 0.573 31 (48) 37 (69) 55 (61) 0. 076
Calcium antagonist, n (%) 7 (18) 18 (16) 0.801 9 (14) 6 (11) 23 (26) 0.055
Diuretics, n (%) 12 (32) 31 (27) 0.679 16 (25) 16 (30) 31 (34) 0.450
Other Medications
Nitrate, n (%) 5 (13) 7 (6) 0.181 1 (2) 7 (13) 16 (18) 0.008*
Acetyl salicylic acid, n (%) 24 (63) 76 (68) 0.691 38 (60) 40 (74) 65 (73) 0.169
Clopidrogel, n (%) 11 (29) 34 (31) 1.000 13 (21) 18 (33) 28 (32) 0.259
Allopurinol, n (%) 5 (13) 6 (5.4) 0.147 3 (5) 3 (6) 15 (17) 0.022*
Aldosterone antagonist, n (%) 1 (3) 0 (0) 0.248 0 (0) 1 (2) 0 (0) 0.245
Statin, n (%) 16 (42) 60 (53) 0.423 27 (42) 28 (52) 49 (55) 0.598
Values are median (interquartile range) or n (%).a Wilcoxon-Mann-Whitney-Test, Jonckheere-Terpstra test, Fisher or c2 Test were used as appropriate, *
statistically significant (p < 0,05). #Subjects with diabetes before inclusion or new detected diabetes based on oGTT results
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linked to glucose metabolism disorders can contribute
to the development of LVDD and that both are impor-
tant determinants of LVDD. It is well established that
diabetes is associated with chronic HF [25,26]. Previous
studies have shown that IR, independent of hyperglyce-
mia, predisposes the development of systolic HF [14,27].
In a study by Ingelsson et al. [27], IR was the strongest
glucometabolic predictor of chronic HF, even in a sub-
sample without diabetes and independently of other
established risk factors for HF. Our study showed, for
the first time, that IR is a predictor for the prevalence
and severity of LVDD in subjects without overt diabetes.
Since, in our study, IR was associated with LVDD, MetS
Table 3 Parameters of cardiac assessment in IR(+) or IR(-), in subjects with normal glucose metabolism and in different
degrees of glucose metabolism disturbances
Variable IR (+) IR(-) p-value
a NGT IGT T2DM
5# p-value
a
n 38 (18) 113 (54) - 64 (31) 54 (26) 90 (43) -
Diastolic function
Normal DF, n (%) 3 (8) 32 (28) - 24 (38) 8 (15) 6 (7) -
LVDD (any degree), n (%) 35 (92) 81 (72) 0.013* 40 (63) 46 (85) 84 (93) 0.001*
LVDD grade I, n (%) 23 (60%) 54 (48) 0.015* 29 (45) 34 (63) 49 (54) 0.001*
LVDD grade II, n (%) 12 (32) 27 (24) 0.017* 11 (17) 12 (22) 35 (39) 0.001*
IVS (mm) 11(11-13) 11 (10-13) 0.378 11 (10-13) 11 (10-13) 12 (11-14) 0.012*
Echocardiography
PLW (mm) 12 (9-12) 11 (10-13) 0.617 11 (9-13) 11 (10-13) 12 (10-14) 0.053
LVEDD (mm) 47 (43-49) 44 (40-48) 0.084 45 (41-48) 44 (40-49) 44 (39-48) 0.264
LVESD (mm) 30 (27-35) 30 (26-34) 0.984 31 (28-36) 29 (26-34) 28 (24-33) 0.037*
RWT 0.48 (0.44-0.58) 0.51 (0.43-0.62) 0.625 0.49 (0.40-0.58) 0.48 (0.44-0.59) 0.53 (0.46-0.64) 0.012*
LVM (g/m
2) 87 (68-109) 84 (69-104) 0.900 83 (69-100) 84 (68-107) 90 (69-111) 0.430
LA- Index (ml/m
2) 31 (25-38) 30 (24-36) 0.555 28 (24-32) 31 (25-37) 32 (27-38) 0.001*
EF biplan (%) 70 (63-73) 67 (62-71) 0.119 65 (61-70) 67 (63-73) 67 (62-73) 0.205
Smax (cm/s) 6.40 (5.70-7.10) 6.25 (5.50-7.15) 0.883 6.3 (5.6-7.3) 6.3 (5.4-7.0) 6.0 (5.3-7.1) 0.246
VE (cm/s) 70 (60-80) 60 (50-70) 0.155 60 (50-70) 60 (50-80) 70 (60-90) 0.012*
VA (cm/s) 80 (60-90) 70 (60-85) 0.115 70 (55-85) 70 (60-90) 80 (70-90) <0.001*
VE/VA 0.8 (0.7-1.1) 0.9 (0.7-1.1) 0.566 0.9 (0.8-1.2) 0.9 (0.7-1.1) 0.8 (0.7-1.1) 0.218
E ‘ septal (cm/s) 5.7 (4.7-7.1) 6.1 (5.3-7.9) 0.099 6.5 (5.3-8.2) 6.2 (5.3-7.6) 5.6 (4.9-6.6) 0.001*
A ‘ (cm/s) 9.2 (8.0-10.2) 9.6 (8.4-10.4) 0.644 9.7 (8.7-10.4) 9.5 (8.6-10.4) 9.0 (7.810.2) 0.028*
E ‘ lateral (cm/s) 8.3 (6.5-9.1) 8.8 (7.0-10.6) 0.085 9.4 (7.3-10.9) 8.4 (6.6-10.2) 7.7 (6.5-9.2) 0.002*
Overage E’ 7.3 (5.4-7.9) 7.5 (6.2-9.1) 0.061 7.9 (6.3-9.5) 7.3 (5.7-8.7) 6.8 (5.6-7.8) <0.001*
E’/A’ septal 0.6 (0.5-0.8) 0.7 (0.6-0.8) 0.102 0.7 (0.6-0.8) 0.7 (0.6-0.8) 0.7 (0.5-0.7) 0.087
E/E’ septal 11.3 (9.6-15.1) 9.8 (7.7-12.7) 0.014* 8.9 (7.3-11.9) 10.2 (8.5-14.1) 12.2 (9.6-15.3) <0.001*
Overage VE/E’ 9.8 (8.3-11.5) 8.1 (6.6-11.0) 0.011* 7.6 (6.2-10.1) 8.8 (7.4-11.0) 10.5 (8.1-13.2) <0.001*
PVsys (cm/s) 59 (50-66) 60 (51-67) 0.380 59 (50-65) 60 (51-68) 60 (55-68) 0.089
PVdia (cm/s) 46 (38-53) 43 (38-55) 0.839 44 (39-54) 43 (36-52) 46 (40-55) 0.468
PVsys/PVdia 1.2 (1.1-1.5) 1.3 (1.1-1.6) 0.346 1.3 (1.1-1.5) 1.4 (1.1-1.6) 1.4 (1.1-1.6) 0.325
PVa-max (cm/s) 31 (25-34) 31 (28-35) 0.240 31 (28-35) 31 (26-34) 32 (28-35) 0.382
GLS_Avg (-%) 19.3 (21.8-17.0) 19.5 (22.0-17.3) 0.812 20 (22-18) 19 (22-17) 19 (21-17) 0.363
Cardiac assessment
CAD, n (%) 23 (60) 62 (55) 0.339 26 (41) 37 (69) 57 (64) 0.003*
Hx. CABG 1 (3) 5 (5) 0.437 2 (3) 2 (4) 8 (9) 0.223
Hx. PTCA 14 (37) 46 (41) 0.412 14 (22) 28 (52) 43 (49) 0.001*
Hx. MI, n (%) 10 (26) 26 (23) 0.416 7 (11) 19 (35) 16 (18) 0.004*
NYHA (mean, SD) 2.0 (± 0.61) 1.9 (± 0.61) 0.337 1.8 1.8 2.0 0.249
NT-pro-BNP (pg/ml) (143 ± 105-228) 131 (74-280) 0.916 116 (65-123) 126 (75-114) 152 (80-417) 0.283
CAD = coronary artery disease, CABG = coronary artery bypass graft, DF = diastolic function, GLS = global longitudinal strain, Hx = history off, IVS =
intraventricular septum, LA= left atrium, LVEDD = left ventricular enddiastolic diameter, LVESD = left ventricular endsystolic parameter, EF = ejection fraction,
LVMi = left ventricular mass index, E ‘= early diastolic tissue doppler velocity, PVsys = systolic pulmonary vein flow velocity, PVdia = diastolic pulmonary vein flow
velocity, PTCA = Percutaneous transluminal coronary angioplasty, PLW = posterolateral wall, RWT = relative wall thickness, SD = Standard deviation, Smax =
maximal systolic velocity at the septal mitral annulus, VA = late diastolic transmitral inflow velocity, VE = early diastolic transmitral inflow velocity
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Page 6 of 12Figure 1 Diastolic dysfunction and glucose metabolism. Figure 1 illustrates the prevalence of mild and moderate to severe diastolic
dysfunction in patients with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and type 2 diabetes (T2DM). LVDD = left
ventricular diastolic dysfunction
Figure 2 E/E’average ratio in subjects with normal glucose tolerance, impaired glucose tolerance and diabetes. Figure 2 illustrates the E/
E’ ratio in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and type 2 diabetes (T2DM).
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Page 7 of 12Figure 3 HOMA-IR Quartile and the overall prevalence of diastolic dysfunction. Figure 3 illustrates the prevalence of LVDD in relation to
different quartiles of the HOMA-IR. LVDD = left ventricular diastolic dysfunction
Figure 4 Average E/E’ratio in subjects with or without insulin resistance or diabetes. Figure 3 illustrates the E/E’average ratio in subjects
with or without insulin resistance (IR) or diabetes.
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Page 8 of 12and obesity and LVDD was associated with increased
BMI and waist circumference, previous described asso-
ciation between obesity and diastolic HF may be
mediated, at least in part, by IR.
This is of clinical relevance, since it has been demon-
strated that subtle and subclinical signs of LVDD are
associated with an increased cardiovascular morbidity
and mortality [3,9,28]. In a study by Wang et al. [29],
including subjects with cardiac diseases and controls, a
reduced E’ velocity was an independent predictor of car-
diac death, and From et al. [30] demonstrated an asso-
ciation of increasing E/E’ ratio with all-cause mortality
in patients with diabetes. Mogelvang et al. [4] showed
that, in the general population, LVDD diagnosed by TDI
was a powerful and independent predictor of death.
Recently, the predictive value of asymptomatic early dia-
stolic dysfunction for HF has been appreciated [29], and
asymptomatic early diastolic dysfunction is the most
prominent characteristic of diabetic cardiomyopathy
[8,31]. Our findings may indicate that the risk for
LVDD is already increased in the subclinical phase of
glucose metabolism disturbances in subjects with IR,
which may precede the development of diabetes. This
information would be of clinical importance, because it
might strongly justify and encourage the use of thera-
peutic interventions, including drugs capable of improv-
ing insulin sensitivity, with the aim of reducing the risk
for diabetic cardiomyopathy.
Pathophysiological considerations
Although establishing a pathophysiological model linking
IR to LVDD is beyond the scope of the present study, sev-
eral mechanisms for a conditional relationship between IR,
glucose metabolism and LVDD should be considered.
These mechanism most prominent includes altered insulin
signaling, deposition of advanced nonenzymatic glycation
end products (AGE) into the ECM [32], increased myocar-
dial collagen deposition with down- regulation of matrix
metalloproteinases (MMPs) and upregulation of tissue
inhibitors of metalloproteinases (TIMPs) [33], and sub-
strate shifts from glucose to free fatty acids [34] as well as
endothelial dysfunction [35].
In our study, the majority of subjects with IR and IGT
had a mild form of LVDD (grade I, relaxation abnormal-
ities). Since relaxation is an active, dynamic and energy-
consuming myocardial process, impaired relaxation may
be due to a reduction in the energy supply. The above
mentioned abnormalities in the free acid metabolism
may be important contributors to the abnormal myocar-
dial relaxation in subjects with IR. High levels of free
acids lead to an inhibition of glucose oxidation, resulting
in reduced myocardial ATP availability [36].
In addition, IR can lead to sympathetic nervous system
activation [37], which is related to an increased response
to angiotensin II [38] and increases the stimulating
effects of angiotensin II on collagen production [39],
leading to fibrosis and likely subsequent the develop-
ment of LVDD. Alterations in myocardial structure are
usually minimal in the early stages of diabetes and may
be partially reversible. As the disease progresses, accu-
mulation of collagen becomes obvious and may play a
major role in the development of LVDD [40]. Further-
more, insulin resistance independently influences arterial
stiffness [41], and MacIsaac et al [42] demonstrated a
link between arterial resistance and diastolic dysfunction
in type 2 diabetes, indicating that vascular and LVDD in
glucose metabolism disturbances are manifestations of
common pathophysiological mechanisms.
Interestingly, even in subjects without a history of dia-
betes before inclusion into the study, the HbA1c was
significantly correlated with the E/E’ratio, a parameter
indicative for LVDD with elevated filling pressures. In
addition, HbA1c correlated with the LAi, a parameter
that indicates long standing LVDD. As the HbA1c
incorporates metabolic disturbances over a longer per-
iod of time, the LAi reflects a cumulative effect of differ-
ent contributors to LVDD of longer duration and is less
vulnerable to acute changes in preload and afterload,
which might have an acute impact on diastolic function.
Therefore, the LAi could be labeled as the “HbA1c” of
diastolic dysfunction abnormalities.
Clinical context
Two recent studies, the “ADVANCE” trial [43] and the
“ACCORD"- trial [44], reported no significant benefit
from intensive HbA1c lowering in terms of cardiovascular
outcomes in subjects with long standing diabetes. Simi-
larly, outcomes of recent trials in subjects with HFnEF
were frequently disappointing [45-48]. The average dura-
tion of diabetes at the start of the “ACCORD” and
“ADVANCED” studies ranged from 8 to 11,5 years. Sub-
group analysis in “ACCORD” showed that intensive gly-
caemic control led to fewer cardiovascular complications
in diabetic subjects with shorter disease duration and with
no antecedent cardiovascular events at baseline. The cardi-
ovascular benefit of intensive glycaemic control in subjects
with shorter diabetes duration and no pre-existing cardio-
vascular disease was also supported by the follow up of
the United Kingdom Prospective Diabetes Study (UKPDS)
patients [49]. Analogous, the neutral outcome in HFnEF
trials might be attributed to the recruitment of patients
with advanced diastolic HF and concomitant reduced sys-
tolic function, indicating long standing myocardial disease.
Likely, therapeutic interventions have failed because the
myocardial damage might have become partly irreversible.
Therefore, we speculate that an early intervention is
necessary to avoid or reverse LVDD as the first stage in
the development of diabetic cardiomyopathy [8,50].
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Page 9 of 12Early treatment strategies should address functional
myocardial abnormalities characteristically observed in
subjects with diabetes, IR and MetS such as a shift in
the myocardial metabolism from glucose to free fatty
acids or changes in the ECM turnover. Thiazolidine-
diones, which are capable to restore glucose utilization,
have recently been shown to favorably modify diastolic
function as evident from improvement the in E’septal
velocity [51]. In this content, one should recognize that
physical activity, which can improve insulin sensitivity,
was shown to prevent the development of cardiovascular
diseases in type 2 diabetes and can improve diastolic
function and exercise capacity in subjects with diastolic
heart failure [52].
Limitations
In our study, we did not use the gold standard in the
assessment of insulin sensitivity, i.e. glucose clamp [53].
However, previous studies have shown that HOMA-IR
is strongly related to clamp-measured insulin resistance
in both diabetic and non diabetic subjects [19,54].
Therefore, the HOMA-IR seems to be a reliable diag-
nostic tool and practicable alternative in the clinical set-
ting in the assessment of IR. Furthermore, the rates of
CAD and cardiovascular risk factors were high in this
study population. Therefore, the present results may not
be readily represent the general population. Neverthe-
less, association between LVDD, IR and glucose metabo-
lism remains significant after adjustment for CAD and
hypertension as covariates into multivariate regression
models. Although we based the diagnosis of LVDD on
current guidelines which have recently been published
[18], their clinical value has yet to be prospectively vali-
dated. Lastly, our cross sectional study design does not
permit any conclusions on causality.
Conclusion
The present study suggests that IR and glucose metabo-
lism disorders are independently associated with LVDD,
supporting the relevance of LVDD in the development of
diabetic cardiomyopathy. Patients with IR and glucose
metabolism disorders might represent a target population
to prevent the development of HF. Screening programs
should address the assessment of diastolic function and
therapeutic options capable of improving insulin sensitiv-
ity might be considered in the treatment of these patients
at risk for the development of heart failure.
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